"Bridged-Ring Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic hydrocarbons that contain multiple rings which share one or more bridgehead connections.
| Descriptor ID |
D001952
|
| MeSH Number(s) |
D02.455.426.100 D04.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bridged-Ring Compounds".
Below are MeSH descriptors whose meaning is more specific than "Bridged-Ring Compounds".
This graph shows the total number of publications written about "Bridged-Ring Compounds" by people in this website by year, and whether "Bridged-Ring Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged-Ring Compounds" by people in Profiles.
-
Le NDB, Yesilbag Tonga G, Mout R, Kim ST, Wille ME, Rana S, Dunphy KA, Jerry DJ, Yazdani M, Ramanathan R, Rotello CM, Rotello VM. Cancer Cell Discrimination Using Host-Guest "Doubled" Arrays. J Am Chem Soc. 2017 06 14; 139(23):8008-8012.
-
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: The watershed for treatment selection? Cancer Treat Rev. 2016 Feb; 43:27-35.
-
Kim C, Tonga GY, Yan B, Kim CS, Kim ST, Park MH, Zhu Z, Duncan B, Creran B, Rotello VM. Regulating exocytosis of nanoparticles via host-guest chemistry. Org Biomol Chem. 2015 Feb 28; 13(8):2474-2479.
-
Yeh YC, Rana S, Mout R, Yan B, Alfonso FS, Rotello VM. Supramolecular tailoring of protein-nanoparticle interactions using cucurbituril mediators. Chem Commun (Camb). 2014 May 30; 50(42):5565-8.
-
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2012 Oct; 12(5):322-30.
-
Patil RA, Kolewe ME, Normanly J, Walker EL, Roberts SC. Contribution of taxane biosynthetic pathway gene expression to observed variability in paclitaxel accumulation in Taxus suspension cultures. Biotechnol J. 2012 Mar; 7(3):418-27.
-
De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010 Jan 01; 28(1):149-53.